CD28 and central nervous system cancer: generated a CAR‐T construct by using scFv derived from an IL‐13Rα2 specific monoclonal antibody fused with a murine IgG leader peptide, the hinge region of murine IgG1, the CD28 transmembrane domain, and the CD28 and CD3ζ signalling domains to study the therapeutic potential of CAR‐T cells in a murine model of glioma.42